JanOne advances non-addictive pain treatments: what it means for JanOne stock

Published on 10/05/2026 at 01:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JanOne develops non-addictive pain treatments. JanOne stock reflects a biotechnology mission targeting severe pain and opioid reduction.

JAN, US47089W1045, Illustration mit AI erstellt.

JanOne (ISIN US47089W1045) had a prior close of EUR 0.45 at Lang & Schwarz for the October 2, 2026 trading session. The company is developing non-addictive approaches to severe pain, giving JanOne stock a biotechnology profile rather than a conventional income or property story.

Non-addictive treatments define the mission

According to JanOne, its mission is to bring treatments to market for diseases that cause severe pain and to find alternatives that reduce reliance on opioid prescriptions. The company describes itself as a biotechnology business focused on treating disease at its source.

That positioning places clinical development at the center of the equity story. Revenue, earnings and approval milestones would therefore matter more than a recurring property portfolio or a fixed lending spread when the company is assessed.

Small-cap market data remain volatile

The EUR 0.45 prior close is the key dated market reference for the October 2, 2026 session. It also provides a concrete comparison with the EUR 0.45 price shown by Parqet in its September 2026 U.S. dividend-stock table, which listed a 32.03 percent dividend yield for JanOne on June 24, 2026.

The comparison is historical rather than a new operating result. It shows why the quotation date matters for a low-priced biotechnology company, where a yield calculation can change sharply when the share price moves even if the stated payout does not.

NYSE identity and business scope

MarketBeat identifies JanOne as a technology and life sciences company traded under the JAN symbol on the NYSE, with activities addressing the opioid crisis and related healthcare needs. The company has also pursued technology and financial-services initiatives, creating a broader scope than a single drug candidate.

For investors, the central distinction is between the stated mission and measurable clinical progress. The October 2, 2026 reference close of EUR 0.45 supplies the market anchor, while the biotechnology description explains the potential operating path without turning the business model into an earnings forecast.

Prior close sets the reference

JanOne's prior close at Lang & Schwarz was EUR 0.45 for the October 2, 2026 trading session. The dated quotation and the 32.03 percent historical yield figure should be read separately because they refer to different market dates.